Fluoroquinolones Up Risk for Severe Dysglycemia in DiabetesFluoroquinolones Up Risk for Severe Dysglycemia in Diabetes

Use of fluoroquinolones, in particular moxifloxacin, appears to increase the risk of severe blood glucose swings in patients with diabetes compared with the use of other classes of antibiotic. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Related Links:

Johns Hopkins Children's Center has been ranked as the best pediatric hospital in the state, and once again as one of the 10 best in the country, according to U.S. News&World Report. The annual Best Children’s Hospitals rankings are intended to help families of children with complex and rare conditions find the best medical care. The rankings highlight the top 50 hospital centers in 10 pediatric specialties: cancer, cardiology and heart surgery, diabetes and endocrinology, g astroenterology and…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Phosphorylation of dynamin-related protein 1 (Drp1) represents an important regulatory mechanism for mitochondrial fission. Here, we established the role of Drp1 serine 600 (Drp1S600) phosphorylation in mitochondrial fission in vivo and assessed the functional consequences of targeted elimination of the Drp1S600 phosphorylation site in the progression of diabetic nephropathy (DN). We generated a knockin mouse in which S600 was mutated to alanine (Drp1S600A). We found that diabetic Drp1S600A mice exhibited improved biochemical and histological features of DN along with reduced mitochondrial fission and diminished mitochondr...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Dipeptidyl peptidase-4 inhibitors (DPP-4i) are emerging glucose-lowering agents through interacting with DPP-4 substrate, impact of which on systemic inflammation in type 2 diabetes mellitus (T2DM) remains unk...
Source: Lipids in Health and Disease - Category: Lipidology Authors: Tags: Research Source Type: research
ConclusionsRenal biopsies, while not commonly performed in children with SCD, were universally abnormal. Outcomes were poor in this cohort of patients despite a variety of post-biopsy interventions. Effective early intervention to prevent chronic kidney disease (CKD) is needed to reduce morbidity and mortality in children with SCD.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
ConclusionsOnce-weekly trelagliptin 100  mg administered for 12 weeks resulted in a numerically, but not statistically, greater improvement in QOL and treatment satisfaction versus daily DPP-4 inhibitors. The decision to administer once-weekly or daily DPP-4 inhibitor treatment is likely to depend on patient preferences and the treatmen t policies of physicians.Trial RegistrationClinicalTrials.gov (NCT03014479) and JAPIC (JapicCTI-173482).FundingTakeda Pharmaceutical Company Ltd.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Because of metabolic dysfunction, high glucose levels represent good nutrition for bacteria on the skin, on the ocular surface (OS) and in the tears of type 2 diabetes mellitus patients, affecting the conjunctival bacterial community. Previously, the only method used to The OS bacterial flora of type 2 diabetes mellitus patients and healthy subjects were compared using 16SrRNA sequencing-based bacterial identification. Among 23 healthy subjects (CON) and 31 type 2 diabetes mellitus patients (DM), 54 eyes were enrolled to investigate the composition of the OS bacterial community. Factors potentially modifying the microbiota...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Latest analysis of CREDENCE with SGLT2 inhibitor canagliflozin shows the agent has a cardio- and renal-protective effect in both primary and secondary CV prevention populations.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
June 17, 2019 -- The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
ADA 2019--Linagliptin, the DPP-4 inhibitor, showed similar risk for first or recurrent CV events or hopspitalization vs placebo in T2DM patients with high cardiorenal risk in CARMELINA subanalysis.
Source: ConsultantLive - Category: Internal Medicine Authors: Tags: Cardiovascular Disease Diabetes Diabetes Type 2 Source Type: news
More News: Avelox | Diabetes | Endocrinology | Health | Moxifloxacin